MarketPulse

RAD 402

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Radiopharm Theranostics

Radiopharm Theranostics Advances Pipeline as Cash Dwindles to $19.2M

Radiopharm completes Phase 2b enrollment for brain imaging agent RAD 101 with 90% MRI concordance, initiates new trials while cash reserves fall sharply.
RADXclinical trialsradiopharmaceuticals
GlobeNewswire Inc.GlobeNewswire Inc.··Radiopharm Theranostics

Radiopharm Theranostics Advances Novel Prostate Cancer Therapy With First Patient Dosed

Radiopharm Theranostics doses first patient in Phase 1 trial of RAD 402, a targeted radioimmune therapy for advanced prostate cancer, with data expected H2 2026.
RADXmonoclonal antibodyPhase 1 clinical trial